These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 32376182)
1. Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients with Hepatitis C and Hepatocellular Carcinoma. Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS J Vasc Interv Radiol; 2020 Jun; 31(6):953-960. PubMed ID: 32376182 [TBL] [Abstract][Full Text] [Related]
2. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C; J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157 [TBL] [Abstract][Full Text] [Related]
3. Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma. Kamp WM; Sellers CM; Stein S; Lim JK; Kim HS Sci Rep; 2019 Nov; 9(1):17081. PubMed ID: 31745132 [TBL] [Abstract][Full Text] [Related]
4. Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma. Singal AG; Rich NE; Mehta N; Branch AD; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Ioannou GN; Huang A; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Kagan S; Gopal P; Wong R; Parikh ND; Murphy CC Gastroenterology; 2019 Nov; 157(5):1253-1263.e2. PubMed ID: 31374215 [TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma incidence post direct-acting antivirals in hepatitis C-related advanced fibrosis/cirrhosis patients in Australia. Chan PPY; Levy MT; Shackel N; Davison SA; Prakoso E Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):541-546. PubMed ID: 32660841 [TBL] [Abstract][Full Text] [Related]
6. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617 [TBL] [Abstract][Full Text] [Related]
7. The influence of direct-acting antivirals in hepatitis C virus related hepatocellular carcinoma after curative treatment. Kuo YH; Wang JH; Chang KC; Hung CH; Lu SN; Hu TH; Yen YH; Kee KM; Chen CH Invest New Drugs; 2020 Feb; 38(1):202-210. PubMed ID: 31701431 [TBL] [Abstract][Full Text] [Related]
9. The Impact of Direct-acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients With Hepatocellular Carcinoma Listed for Liver Transplantation: An International Multicenter Study. Gorgen A; Galvin Z; Huang AC; Vinaixa C; O'Rourke JM; Francoz C; Hansen BE; Durand F; Elsharkawy AM; Shah T; Berenguer M; Rubin A; Calatayud D; Mehta N; Terrault NA; Lilly LB; Selzner N; Sapisochin G Transplantation; 2020 Oct; 104(10):2087-2096. PubMed ID: 31978002 [TBL] [Abstract][Full Text] [Related]
10. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection. Ooka Y; Miho K; Shuntaro O; Nakamura M; Ogasawara S; Suzuki E; Yasui S; Chiba T; Arai M; Kanda T; Maruyama H; Yokosuka O; Kato N; Mochizuki H; Omata M Hepatol Int; 2018 Nov; 12(6):523-530. PubMed ID: 30242733 [TBL] [Abstract][Full Text] [Related]
11. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Singal AG; Rich NE; Mehta N; Branch A; Pillai A; Hoteit M; Volk M; Odewole M; Scaglione S; Guy J; Said A; Feld JJ; John BV; Frenette C; Mantry P; Rangnekar AS; Oloruntoba O; Leise M; Jou JH; Bhamidimarri KR; Kulik L; Tran T; Samant H; Dhanasekaran R; Duarte-Rojo A; Salgia R; Eswaran S; Jalal P; Flores A; Satapathy SK; Wong R; Huang A; Misra S; Schwartz M; Mitrani R; Nakka S; Noureddine W; Ho C; Konjeti VR; Dao A; Nelson K; Delarosa K; Rahim U; Mavuram M; Xie JJ; Murphy CC; Parikh ND Gastroenterology; 2019 May; 156(6):1683-1692.e1. PubMed ID: 30660729 [TBL] [Abstract][Full Text] [Related]
12. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients. Cucchetti A; D'Amico G; Trevisani F; Morelli MC; Vitale A; Pinna AD; Cescon M; Dig Liver Dis; 2018 Feb; 50(2):156-162. PubMed ID: 29102521 [TBL] [Abstract][Full Text] [Related]
13. Surgical outcomes for hepatocellular carcinoma detected after hepatitis C virus eradiation by direct-acting antivirals. Tanaka S; Shinkawa H; Tamori A; Takemura S; Takahashi S; Amano R; Kimura K; Ohira G; Kawada N; Kubo S J Surg Oncol; 2020 Dec; 122(8):1543-1552. PubMed ID: 32856301 [TBL] [Abstract][Full Text] [Related]
14. [The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma]. Takahashi A; Shima T; Kinoshita N; Yano K; Ueno T; Nishiwaki M; Yamamoto Y; Oya H; Amano I; Matsumoto J; Mitsumoto Y; Tanaka I; Sakai K; Sawai N; Mizuno C; Mizuno M; Itoh Y; Okanoue T Nihon Shokakibyo Gakkai Zasshi; 2018; 115(2):184-194. PubMed ID: 29459562 [TBL] [Abstract][Full Text] [Related]
15. Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents. Ohama H; Hiraoka A; Tada T; Kariyama K; Itobayashi E; Tsuji K; Ishikawa T; Toyoda H; Hatanaka T; Kakizaki S; Naganuma A; Tada F; Tanaka H; Nakamura S; Nouso K; Tanaka K; Kumada T; J Gastroenterol Hepatol; 2024 Jul; 39(7):1394-1402. PubMed ID: 38602340 [TBL] [Abstract][Full Text] [Related]
16. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review. Singal AG; Lim JK; Kanwal F Gastroenterology; 2019 Jun; 156(8):2149-2157. PubMed ID: 30878469 [TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694 [TBL] [Abstract][Full Text] [Related]
18. Impact of direct-acting antiviral therapy for hepatitis C-related hepatocellular carcinoma. Lin WC; Lin YS; Chang CW; Chang CW; Wang TE; Wang HY; Chen MJ PLoS One; 2020; 15(5):e0233212. PubMed ID: 32442193 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. Li T; Qu Y; Guo Y; Wang Y; Wang L Liver Int; 2017 Jul; 37(7):974-981. PubMed ID: 27943605 [TBL] [Abstract][Full Text] [Related]
20. Cure With Interferon-Free Direct-Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virus-Related Hepatocellular Carcinoma From Both East and West. Dang H; Yeo YH; Yasuda S; Huang CF; Iio E; Landis C; Jun DW; Enomoto M; Ogawa E; Tsai PC; Le A; Liu M; Maeda M; Nguyen B; Ramrakhiani N; Henry L; Cheung R; Tamori A; Kumada T; Tanaka Y; Yu ML; Toyoda H; Nguyen MH Hepatology; 2020 Jun; 71(6):1910-1922. PubMed ID: 31610027 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]